Cargando…

Global Health Innovation Technology Models

Chronic technology and business process disparities between High Income, Low Middle Income and Low Income (HIC, LMIC, LIC) research collaborators directly prevent the growth of sustainable Global Health innovation for infectious and rare diseases. There is a need for an Open Source-Open Science Arch...

Descripción completa

Detalles Bibliográficos
Autor principal: Harding, Kimberly
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998271/
https://www.ncbi.nlm.nih.gov/pubmed/29942382
http://dx.doi.org/10.5772/62921
_version_ 1783331213826588672
author Harding, Kimberly
author_facet Harding, Kimberly
author_sort Harding, Kimberly
collection PubMed
description Chronic technology and business process disparities between High Income, Low Middle Income and Low Income (HIC, LMIC, LIC) research collaborators directly prevent the growth of sustainable Global Health innovation for infectious and rare diseases. There is a need for an Open Source-Open Science Architecture Framework to bridge this divide. We are proposing such a framework for consideration by the Global Health community, by utilizing a hybrid approach of integrating agnostic Open Source technology and healthcare interoperability standards and Total Quality Management principles. We will validate this architecture framework through our programme called Project Orchid. Project Orchid is a conceptual Clinical Intelligence Exchange and Virtual Innovation platform utilizing this approach to support clinical innovation efforts for multi-national collaboration that can be locally sustainable for LIC and LMIC research cohorts. The goal is to enable LIC and LMIC research organizations to accelerate their clinical trial process maturity in the field of drug discovery, population health innovation initiatives and public domain knowledge networks. When sponsored, this concept will be tested by 12 confirmed clinical research and public health organizations in six countries. The potential impact of this platform is reduced drug discovery and public health innovation lag time and improved clinical trial interventions, due to reliable clinical intelligence and bio-surveillance across all phases of the clinical innovation process.
format Online
Article
Text
id pubmed-5998271
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher SAGE Publications
record_format MEDLINE/PubMed
spelling pubmed-59982712018-06-25 Global Health Innovation Technology Models Harding, Kimberly Nanobiomedicine (Rij) Nanobiomedicine Chronic technology and business process disparities between High Income, Low Middle Income and Low Income (HIC, LMIC, LIC) research collaborators directly prevent the growth of sustainable Global Health innovation for infectious and rare diseases. There is a need for an Open Source-Open Science Architecture Framework to bridge this divide. We are proposing such a framework for consideration by the Global Health community, by utilizing a hybrid approach of integrating agnostic Open Source technology and healthcare interoperability standards and Total Quality Management principles. We will validate this architecture framework through our programme called Project Orchid. Project Orchid is a conceptual Clinical Intelligence Exchange and Virtual Innovation platform utilizing this approach to support clinical innovation efforts for multi-national collaboration that can be locally sustainable for LIC and LMIC research cohorts. The goal is to enable LIC and LMIC research organizations to accelerate their clinical trial process maturity in the field of drug discovery, population health innovation initiatives and public domain knowledge networks. When sponsored, this concept will be tested by 12 confirmed clinical research and public health organizations in six countries. The potential impact of this platform is reduced drug discovery and public health innovation lag time and improved clinical trial interventions, due to reliable clinical intelligence and bio-surveillance across all phases of the clinical innovation process. SAGE Publications 2016-01-01 /pmc/articles/PMC5998271/ /pubmed/29942382 http://dx.doi.org/10.5772/62921 Text en © 2016 Author(s). Licensee InTech. http://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Nanobiomedicine
Harding, Kimberly
Global Health Innovation Technology Models
title Global Health Innovation Technology Models
title_full Global Health Innovation Technology Models
title_fullStr Global Health Innovation Technology Models
title_full_unstemmed Global Health Innovation Technology Models
title_short Global Health Innovation Technology Models
title_sort global health innovation technology models
topic Nanobiomedicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5998271/
https://www.ncbi.nlm.nih.gov/pubmed/29942382
http://dx.doi.org/10.5772/62921
work_keys_str_mv AT hardingkimberly globalhealthinnovationtechnologymodels